Han Y.-F.,Burns Institute |
Han Y.-Q.,Wuhan Institute of Technology |
Pan Y.-G.,The Peoples Hospital of Qidong city |
Chen Y.-L.,Shanghai University |
Chai J.-K.,Burns Institute
Transplantation Proceedings | Year: 2010
Background: Cell-based gene therapy using cells that express angiogenic factors is an alternative technique for therapeutic angiogenesis in transplantation of xenogeneic acellular dermis matrix (ADM). However, immune rejection is a substantial obstacle to implantation of genetically engineered allogeneic or xenogeneic cells. Objective: To evaluate application of microencapsulated cells that express vascular endothelial growth factor (VEGF) in xenogeneic ADM transplants to improve wound angiogenesis and healing. Materials and Methods: NIH3T3 cells were genetically modified to secrete VEGF and enveloped in semipermeable microcapsules. Microencapsulated VEGF-NIH3T3 cells were implanted in defects on the dorsa of guinea pigs with xenogeneic ADM and autologous split-thickness skin grafts. Cell structure and microencapsulation were observed at microscopy, and expression of VEGF was detected using an enzyme-linked immunosorbent assay (ELISA) and immunochemistry. Extent of angiogenesis in the ADM and the survival rate of the composite skin were evaluated after 2 weeks. In addition, expression of human VEGF and CD31 in the implanted acellular dermis was assessed, and microvessel density was calculated. Results: Microencapsulated VEGF-expressing NIH3T3 cells were prepared successfully, and demonstrated proliferation and viability, and expressed VEGF both in vitro and in vivo. Extent of angiogenesis and survival rate of the composite skin containing the microencapsulated VEGF-expressing cells were significantly greater than in controls. Microencapsulated VEGF-expressing NIH3T3 cells augmented early angiogenesis in ADM implanted on wound and improved healing. Conclusion: Microencapsulated xenogeneic cell-based gene therapy may be a novel approach to therapeutic angiogenesis in transplantation of xenogeneic ADM skin. © 2010 Elsevier Inc. All rights reserved.
Zhao G.-J.,Wenzhou Medical College |
Lu Z.-Q.,Wenzhou Medical College |
Yao Y.-M.,Burns Institute
Progress in Biochemistry and Biophysics | Year: 2010
Mitofusin-2 (Mfn2) is a highly conserved transmembrane GTPase which plays a critical role in mitochondrial fusion process. Recent data have been demonstrated that Mfn2 is involved in the regulation of several crucial cellular pathways beyond fusion, including mitochondrial metabolism, cellular signaling cascade, apoptosis and proliferation. With multiple functions and complex mechanisms, Mfn2 might play potential role in the applications in modern medicine. The structure and basic biological function of Mfn2 were summarized, furthermore, the dysfunction of Mfh2 in certain diseases and its therapeutic value were also discussed.
Xu Y.,Zhejiang University |
Xu Y.,Burns Institute |
Xu Y.,Nankai University |
Huang S.,Burns Institute |
Fu X.,Burns Institute
Clinical and Experimental Dermatology | Year: 2012
Hypertrophic scars resutl from abnormal healing of severe burns, and are characterized by loss of the original structure and function of the skin. Transplantation of autologous split skin is the preferred treatment after scar excision; however, there will be some unavoidable degree of contraction within the grafts. To our knowledge, it is very rare that bone marrow-derived mesenchymal stem cells (BM-MSCs) have been used for the treatment of skin-graft contraction. However, in our clinics, we found that during a 2-year follow-up analysis, areas treated with autologous BM-MSCs combined with transplantation of split skin were less likely to have contraction of the skin grafts than areas treated with skin grafts alone. This result indicates that BM-MSCs may be a potential and promising treatment to prevent contraction of skin grafts. © The Author(s) CED © 2012 British Association of Dermatologists.